Difference between revisions of "CT Volumetry Biomarker Ctte"
|Line 10:||Line 10:|
Revision as of 01:32, 15 January 2009
Volumetric CT Technical Committee
The Volumetric X-Ray Computed Tomography (CT) Technical Subcommittee of the Quantitative Imaging Biomarker Alliance has been charged with investigating the technical feasibility and medical value of quantifying longitudinal changes in volume with CT. The initial emphasis will address the following objectives:
- Characterize the precision and accuracy of volumetric tumor measurements. This will be an essential prelude for understanding the threshold that will be needed to classify longitudinal changes in tumor volume as medically meaningful surrogates for changes in health status.
- Compare the sensitivity of volumetric measurements to RECIST/ World Health Organization (WHO) (conventional & modified) outcome measures. This will be necessary in order to determine if Progressive Disease can be detected significantly sooner with volumetric techniques than with uni- or bi-dimensional line-lengths placed on a single slice.
Quantitative Response Metrics for Lung Cancer was selected as a good concrete focus to get started.
Write Profile documents to which equipment and sites can conform to accomplish Quantification goals.
Validate key concepts and answer key questions needed to write the Profiles and demonstrate their effectiveness.
- VolCT - Group 1A - Analyze Bias/Variance where Ground Truth is Known Deterministically
- VolCT - Group 1B - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings
- VolCT - Group 1C - Model Sources of Variability from a Systems Engineering Analysis
- VolCT - Group 2 - Set Standards for using Volumetric Imaging in Clinical Trials
- Initial Target Selection - describing the early prioritization discussions and settling on Lung Tumor Volumes
- Sources of Variability - Andrew Buckler
- Validation Roadmap - P. David Mozley, MD
- Process Groundwork & Profiling - Kevin O'Donnell - See also the Wiki Version